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Abstract: The present study was designed to de-
termine the correlation among dehydroepiandros-
terone (DHEA), cortisol plasma levels, and im-
mune functionality at the time of vaccination with
antibody response to influenza vaccination in young
and old, healthy volunteers. Fifty-two elderly sub-
jects, ages 63–85 years, and 14 young subjects, ages
26–41 years, entered the study. Plasma levels of
DHEA and cortisol and in vitro cytokine production
in response to lipopolysaccharide (LPS) and phyto-
haemagglutinin (PHA) by peripheral blood leuko-
cytes were assessed at the time of vaccination, and
antibody titer was measured before and 18 days after
influenza virus vaccination. Elderly subjects were
characterized by an increase in the cortisol:DHEA
ratio, mainly as a result of a decrease in DHEA. A
decrease in LPS-induced tumor necrosis factor 
(TNF-), increased PHA-induced interleukin-10 (IL-
10) release, and similar PHA-induced interferon-
production were observed in elderly subjects com-
pared with young volunteers. Lower antibody titer to
influenza A virus was observed in elderly individuals,
and the seroconversion factor was found to be cor-
related inversely with IL-10 production and corre-
lated directly with TNF- production and to a lesser
extent, with the plasma level of DHEA. These results
suggest that altered cytokine production in elderly
subjects at the moment of vaccination can be predic-
tive of a low response to influenza vaccination and
warrant the study of strategies to improve protection
afforded by the use of vaccines. J. Leukoc. Biol. 80:
376–382; 2006.
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INTRODUCTION
Influenza is an acute respiratory illness of global importance,
which causes considerable morbidity and mortality every year.
Influenza virus can cause substantial morbidity across the age
spectrum. The elderly are, however, especially vulnerable to
the serious complications of influenza, and high rates of influ-
enza-associated excess hospitalization or death, which exceed
by several-fold the rates seen among most other age groups,
have consistently been observed in many countries and across
many seasons [1–3].
Given the increasing proportion of elderly people worldwide,
a better understanding of the causes and mechanisms of im-
munosenescence is crucial to identify whether prevention
might be beneficial to enhance quality of life and to reduce the
cost of medical care in old age. Normal aging is indeed
associated with a number of impaired immune responsiveness,
such as reduction in response to recall antigen, alterations in T
cell functions, which contribute to increased vulnerability to
infectious disease and malignancy, and reduced responses to
preventive vaccination in the elderly [4].
Today, in developed countries, influenza prophylaxis de-
pends on the annual administration of a killed, trivalent influ-
enza vaccine tailored each year to specific strains of the
influenza virus. Vaccine is recommended for all individuals
with chronic, underlying diseases and for those aged 65 years
or older. Unfortunately, the present available influenza virus
vaccine fails to generate protective immunity in 50% of old
individuals [5]. In particular, the seroconversion, after vaccine,
is 50% from 60 to 70 years old, 31% from 70 to 80 years old,
and only 11% after the age of 80. Yet, as far as public health
is concerned, the vaccination reduces the morbidity by 25%,
admission to hospital by 20%, pneumonia by 50%, and mor-
tality by 70% [6].
Improved vaccines or pharmacological intervention, which
can overcome the decline in immune function with aging
and/or induce broader immunity to novel pandemic strains, are
considered a high priority [7, 8].
Many factors contribute to immunosenescence, including
stem-cell defects, thymus involution, aging of resting immune
cells, replicative senescence of clonally expanding cell, defects
in antigen-presenting cells (APC), dysfunction in several signal
transduction pathways, and dysregulation of the cytokine net-
work [9–11]. We have recently shown in rodents and humans
that a decreased expression in receptor for activated C kinase
1 (RACK-1), in the absence of differences in the expression of
total protein kinase C (PKC) isoforms, underlies defective PKC
activation and functional immune impairment with aging, such
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as cytokine production and proliferation [12, 13]. Furthermore,
we found a positive correlation between plasma level of dehy-
droepindrosterone (DHEA), whose levels decrease with aging
[14], and RACK-1 immunoreactivity, suggesting an important
role of this hormone in maintaining RACK-1 expression and
PKC-mediated immune activation in leukocytes [12, 13].
Our understanding of the molecular mechanism of the im-
mune response to influenza virus is still incomplete. During
infection, the influenza virus interacts with airway cells, in-
ducing the release of immunoreactive mediators, which attract
inflammatory cells to the sites of infection and exert antiviral
activities, providing an early defense against viral infection.
Many cytokines are produced, involved in the initiation of the
inflammatory response in addition to the recruitment and ac-
tivation of specific lymphocytes (reviewed in refs. [15, 16]).
The interplay with interleukin (IL)-1, tumor necrosis factor 
(TNF-), interferon (IFN)-/, IL-18, IFN-, and chemokines
forms a complex, positive feed-back network leading to inflam-
matory response and the development of influenza-specific,
cell-mediated immunity. Cytokine gene expression is associ-
ated with the activation of several signal transduction mole-
cules, i.e., nuclear factor-B, activated protein-1, signal trans-
ducer and activator of transcription, and IFN-regulatory factor,
many of which are dependent on PKC activation [17–19].
The purpose of the present study was to investigate if the
age-related impairment of the translocation of PKC, which
underlies downstream defects in the in vitro activation of
immune responses, was also relevant for the in vivo immune
responsiveness, as assessed by response to influenza vaccina-
tion. We tested the hypothesis that an altered function of
immune cells at the moment of vaccination may be in part
responsible for a defective response to the vaccine in the
elderly. We therefore investigated the correlation between
DHEA, cortisol plasma levels, and in vitro cytokine production
at the moment of vaccination with antibody response to influ-
enza vaccination in young and old, healthy volunteers. As a
result of their central role in regulating the immune response,
including viral infection, we investigated the production of
TNF-, IL-10, and IFN- in response to nonantigen-specific
stimuli, such as lipopolysaccharide (LPS) and phytohemagglu-
tinin (PHA), using the whole blood assay, which is a simple
method that reproduces the natural environment (autologous
serum). It was used, as it requires less blood, and the risk of
loss of minor lymphocyte subsets through density gradient is
eliminated [20].
Overall, our study indicates that low plasma level of DHEA,
decreased TNF-, and increased IL-10 production at the mo-
ment of vaccination are associated with lower antibody re-
sponse to influenza vaccination and suggest possible means of
pharmacological modulation of immune functions in the el-
derly.
MATERIALS AND METHODS
Chemicals
LPS from Escherichia coli serotype 0127:B8 and human -actin antibody were
obtained from Sigma Chemical Co. (St. Louis, MO), PHA was from Invitrogen
(Paisley, UK), antibodies against RACK-1 were from Transduction Laborato-
ries (Affinity, Nottingham, UK), and electrophoresis reagents were from Bio-
Rad (Richmond, CA). All reagents were purchased at the highest purity
available.
Study protocol
In this study, a total of 66 healthy subjects living in the same geographical area
of Northern Italy were recruited. These subjects included 52 elderly subjects
(age 73.26.9 years, range 63–85; 37 females and 15 males) and 14 young
subjects (age 30.44.8 years, range 26–41, nine females and five males). All
elderly subjects were functionally independent. The ethical committee of the
local Health Authorities approved the study, and all subjects signed an
informed consent. All the clinical procedures and enrollment of the subjects
were performed according to the guidelines of the Italian Health Authorities
and the Declaration of Helsinki principles. Criteria for exclusion were abnor-
mal laboratory values, medication known to affect the immune system (i.e.,
steroids), or patients suffering from malignancies, inflammations, and infec-
tions.
Prevaccination blood samples were collected just prior to vaccination in the
early morning. Subjects were vaccinated in November 2004 by intramuscular
injection with a commercially available, trivalent 2004/2005 influenza vaccine
containing 15 g haemagglutinin of each of the following strains: A/New
Caledonian/20/99 (H1N1), A/Fujian/411/2002 (H3N2), and B/Shangai/361/
2002. Postvaccination sera were collected 18 days after vaccination at the
same hour. Serum samples were separated into aliquots and stored at –20°C
until assayed. Over 95% of the subject population had received yearly influ-
enza immunization for the past 3 years as part of their routine clinical
preventive care.
Preparation of whole blood cells and cytokine
production
Blood samples were taken by venous puncture with sodium citrate 0.5 M as
anticoagulant. Sodium citrate was chosen instead of heparin or EDTA as
anticoagulant, as functional assays were performed using the whole blood
assay, and heparin may be contaminated with endotoxin; EDTA interferes with
cell activation. Blood samples were diluted 1:10 in cell culture medium RPMI
1640 (Sigma Chemical Co.) containing 2 mM L-glutamine, 0.1 mg/ml strep-
tomycin, 100 IU/ml penicillin. Diluted blood samples were treated in the
presence or absence of LPS at a final concentration of 1 g/ml or PHA, 1.2
g/ml, and incubated for 24 h or 96 h at 37°C in a humidified 5% CO2
incubator for TNF- and IL-10, IFN- release, respectively. As a result of the
variability in stimulation assays, the same lot of each reagent was used in all
experiments. Cell-free supernatants obtained by centrifugation at 1200 revo-
lutions per minute for 5 min were stored at –20°C until measurement. Cytokine
production was assessed by enzyme-linked immunosorbent assay (ELISA)
using commercially available kits (Immunotools, Friesoythe, Germany). Re-
sults are expressed in pg/ml.
Assay for DHEA and cortisol
The levels of DHEA and cortisol in human plasma were determined by a
commercially available enzyme immunoassay (Assay Design, Inc., Ann Arbor,
MI) following the supplier’s instructions. Results are expressed as ng/ml.
Anti-influenza antibody assay
Pre- and postvaccination immunoglobulin G antibody levels to Influenza A
virus (H3N2) were assessed using a commercially available ELISA kit (Adaltis
Italia, Casalecchio di Reno, Italy). Paired pre- and postvaccination sera
samples from the same individual were tested simultaneously. Results are
expressed as antibody titer, calculated using the semiquantitative plot en-
closed in the kit and as the seroconversion factor, which was calculated as the
ratio of the mean titer before vaccination:titer after vaccination.
Western blot analysis
For RACK-1 and -actin expression in leukocytes, 1.0 ml blood was treated
with ammonium chloride to remove red cells, and then the remaining leuko-
cytes were lysed in 100 l homogenization buffer (50 mM Tris, 150 mM NaCl,
5 mM EDTA, pH 7.5, 0.5% Triton X-100, 50 M phenylmethylsulfonyl
fluoride, 2 g/mL aprotinin, 1 g/mL pepstatin, and 1 g/mL leupeptin) and
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denatured for 10 min at 100°C [21]. The protein content of the cell lysate was
measured using a commercial kit (Bio-Rad). The cell proteins (30 g) were
electrophoresed into a 12% sodium dodecyl sulfate-polyacrylamide gel under
reducing conditions. The proteins were then transferred to polyvinylidene
difluoride membranes (Amersham, Little Chalfont, UK). The different proteins
were visualized using RACK-1 (1:2500) and -actin (1:5000) primary anti-
bodies and developed using enhanced chemiluminescence (Amersham). The
image of the immunoblotting was acquired with a Nikon charged-coupled
device video camera module. The optical density of the bands was calculated
and analyzed by means of the Image 1.47 program for digital image processing
(Wayne Rasband, Research Service Branch, National Institute of Mental
Health, National Institutes of Health, Bethesda, MD).
Statistical analysis
Data are expressed as mean  SEM. Statistical analysis was performed using
GraphPad InStat Version 3.0a for Macintosh (GraphPad Software, San Diego,
CA). Statistical differences were determined using the unpaired t-test or a
multiple comparison test, as indicated in the legends. Spearman correlation
was used to analyze the correlation among different parameters considered.
Effects were designated significant if P  0.05.
RESULTS
A total of 66 healthy subjects, 52 elderly (63–85 years old) and
14 young (26–41 years old), were enrolled and completed the
study. The age and sex distributions of the subjects in the study
are shown in Table 1. Blood samples were taken on the same
day of vaccination, prior to injection, for hormone levels,
functional analysis, and influenza A virus antibody titer, and
18 days after vaccination to determine the seroconversion
factor.
Hormone levels
The age-related increase in the cortisol:DHEA ratio is consid-
ered to be the major determinant of immunological changes
observed during aging. As shown in Figure 1, the elderly
subjects enrolled into the study were characterized by a dra-
matic increase in the cortisol:DHEA ratio (calculated as mean
of the individual cortisol:DHEA ratio of each subject): from
7.11  1.14 in the young to 29.8  4.45 in the elderly
(P0.0001). This increase was mainly a result of a significant
reduction in the levels of DHEA (from 27.441.70 to
12.281.10 ng/ml, P0.0001) rather than cortisol, whose
levels only increase slightly in the elderly (from 179.1914.98
to 213.877.60 ng/ml, P	0.0398).
Cytokine production
Confirming our previous results [13], peripheral blood leuko-
cytes obtained from old donors were characterized by a statis-
tically significant reduction in RACK-1 expression: 0.28 
0.02 versus 0.48  0.04 RACK-1:-actin ratio in old versus
young donors, respectively (P0.0001). Compromised signal
transduction machinery is likely to be associated with alter-
ation in response to immune stimulation. Thus, to characterize
the functionality of the immune system in young and elderly
subjects, the production of TNF-, IL-10, and IFN- was
evaluated after in vitro stimulation of whole blood with LPS and
PHA. The optimal time and stimuli concentrations were iden-
tified in preliminary experiments for each cytokine. For TNF-
production, cells were stimulated for 24 h with 1 g/ml LPS,
and for IL-10 and IFN-, cells were stimulated for 96 h with
1.2 g/ml PHA. The spontaneous release of all cytokines
investigated as well as their plasma levels were below the limit
of detection before and after vaccination (data not shown).
Figure 2 shows the production of TNF-, IL-10, and IFN- by
blood cells in young and elderly at the moment of influenza
vaccination. The elderly subjects were indeed characterized by
altered cytokine production. A statistically significant decrease
in LPS-induced TNF- release (from 1152185 in the young
to 79980 pg/ml in the elderly, P	0.0495), a statistically
significant increase in PHA-induced IL-10 release (from
9754.7 to 45834 pg/ml, P0.0001), and similar IFN-
release compared with young subjects (4688424 and
4208252 pg/ml in young and elderly, respectively) were
observed. IL-10 and IFN- production was also assessed fol-
lowing 96 h stimulation with LPS. As observed for stimulation
with PHA, LPS-induced IL-10 production was increased in the
elderly (from 124 pg/ml in the young to 5120 pg/ml in the
elderly, P	0.0108). On the contrary, LPS-induced IFN- pro-
duction was reduced significantly in the elderly (from 42129
pg/ml in the young to 1207 pg/ml in the elderly, P	0.0074).
Antibody response to influenza vaccination and
relationship with cytokine production
To determine the response to influenza vaccination, the anti-
body titer to influenza A virus was assessed before and 18 days
after vaccination. No local adverse effects to the influenza
vaccine were reported in both groups. A lower antibody titer to
influenza A virus following vaccination was observed in aged
individuals (from 786203 in the young to 29157 in the
elderly, P	0.0016). As shown in Figure 3A, the elderly had
a significantly lower seroconversion factor than the young
(from 2.250.35 in the young to 1.080.10 in the elderly,
P0.0001). The seroconversion factor (Fig. 3, B and C) was
correlated directly with plasma level of DHEA (linear correla-
tion r	0.363, P	0.0034) and inversely correlated with IL-10
production (linear correlation r	–0.484, P0.0001). Further-
more, a direct correlation with TNF production (linear corre-
lation r	0.3997, P	0.0012) was observed, and no correlation
was found with IFN- production or with cortisol level (not
shown). Finally, the decreased TNF production was correlated
to plasma levels of DHEA (linear correlation r	0.326,
P	0.0076; not shown), and IL-10 release was strongly corre-
lated (inverse correlation r	–0.490, P0.0001) with the
plasma levels of DHEA (Fig. 4).
DISCUSSION
A predictable influenza pandemic threat has highlighted the
need for more effective influenza vaccines, antiviral drugs, as
TABLE 1. Demographics of Study Participants
Total Men Women
Young 14 (30.41.3) 5 (31.42.4) 9 (29.81.5)
Elderly 52 (73.21.0) 15 (73.12.2) 37 (73.21.0)
Mean of age in years  SE in parentheses.
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well as development of strategies to improve the response in
at-risk populations, such as the elderly [22]. This is particu-
larly stressed by the recent outbreak of avian viruses and the
possibility that these will transfer to humans. Accordingly, the
purpose of the present investigation was to correlate antibody
response to influenza vaccination in young and old, healthy
subjects with hormonal levels and immune functionality, as
assessed by cytokine production, at the moment of vaccination.
In this study, we found that low plasma level of DHEA,
decreased TNF-, and increased IL-10 production at the mo-
ment of vaccination are associated with lower antibody re-
sponse to influenza vaccination.
Fig. 1. Hormone profile of young and elderly subjects at the
moment of influenza vaccination. (A) Plasma level of cortisol. (B)
Plasma levels of DHEA. (C) Ratio cortisol:DHEA. Each value
represents the mean SEM. Statistical analysis has been performed
by unpaired t-test. The P value is reported in the figure.
Fig. 2. Cytokine profile of young and elderly subjects at the moment
of influenza vaccination. (A) LPS-induced TNF- release. (B) PHA-
induced IL-10 release. (C) PHA-induced IFN- release. Whole blood
obtained from healthy donors of different ages was diluted 1:10 and
incubated for 24 h in the presence of LPS (1 g/ml) for TNF- release
and for 96 h in the presence of PHA (1.2 g/ml) for IL-10 and IFN-
release. Cytokine release was assessed by ELISA. Each value repre-
sents the mean  SEM. Statistical analysis has been performed by an
unpaired t-test. The P value is reported in figure.
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The senescent immune system displays reduced responsive-
ness, and this has to be overcome if therapeutic vaccination is
to be of benefit for the patient. Although the defects are quite
well-characterized, the molecular mechanisms, inducing and
sustaining immunosenescence and ways to overcome them, are
still to be explored in more detail. Substantial data from animal
studies have demonstrated a stimulatory effect of DHEA on
immune function. We previously demonstrated in vitro and in
vivo that DHEA can restore the age-related, defective TNF-
production in macrophages and mitogen-induced splenocyte
proliferation [12]. May et al. [23] demonstrated that DHEA
administration reversed corticosteroid and stress-induced in-
hibition of immune function, Loria et al. [24] showed that
DHEA administration has a protective effect against systemic
Coxsackie virus and Herpes simplex type 2 encephalitis, and
Daynes et al. [25] found that it can enhance IL-2 production by
activated murine T cells. In a limited clinical trial, it has been
demonstrated that orally administered DHEA (50 mg/daily) to
elderly men with low-serum DHEA safely activated several
immune functions within 2–20 weeks of treatment, including B
and T cell mitogenic response and PHA-induced IL-2 produc-
tion, suggesting potential therapeutic benefits of DHEA sup-
plementation in immunodeficient states [26]. On the contrary,
although highly effective in sustaining the response to vacci-
nation in aged rodents, a short course of DHEA treatment, 2
days prior and 2 days after vaccination, failed to improve the
age-related, declined response to influenza vaccination in el-
derly human subjects [27]. Overall, too little is known about
the effects of DHEA supplementation on the human immune
system, and it is still premature to relate these findings to
Fig. 3. Seroconversion factor after influenza vaccination and its
correlation with DHEA and IL-10. (A) Seroconversion factor of
elderly and young subjects 18 days after vaccination. The serocon-
version factor was calculated as the ratio of the mean antibody titer
before vaccination:titer after vaccination. Each value represents the
mean  SEM. (B) Correlation between plasma level of DHEA and
seroconversion. (C) Correlation between in vitro PHA-induced IL-10
production by human peripheral blood leukocytes and seroconver-
sion. The correlation analysis of data was performed by linear cor-
relation. The correlation coefficient, r, and P values are reported in
the figure. Each dot represents a donor (n	66).
Fig. 4. Correlation between plasma level of DHEA and in vitro PHA-induced
IL-10 production by human peripheral blood leukocytes. Correlation analysis
of data was performed by linear correlation. The correlation coefficient, r, and
P values are reported in the figure. Each dot represents a donor (n	66).
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routine clinical applications. Nevertheless, in our investiga-
tion, higher baseline DHEA levels were predictive of better
immunization against influenza and may suggest that DHEA
supplementation may be beneficial. Other methods of increas-
ing immune response in the elderly to influenza vaccine may
include the addition of IL-2 to vaccine protocol, the use of
liposome carriers or diphtheria toxoid adjuvants, or using al-
ternative routes of immunization [28–31].
Concerning the immune system functionality, age-related
changes in cytokine production by immune cells are likely to
contribute to the decreased antibody production seen after
influenza vaccination in the elderly. Numerous studies have
investigated the age-related change in cytokine production
after specific and nonspecific stimulation, and contradictory
results have been reported [32–34]. This may be a result of
sample sizes, varying states of health and lifestyle, different
stimuli, and culture conditions. Results from our investigation
show decreased TNF- production, unchanged PHA-induced
IFN- production, and decreased LPS-induced IFN- produc-
tion in the elderly, together with increased mitogen-induced
IL-10 production. IL-10 and TNF- are cytokines, which have
complex and predominantly opposing roles in the activation of
the immune response [35, 36]. The increased production of
IL-10 in the elderly, observed in response to LPS and PHA, is
likely to inhibit the maturation of APC, hampering, together
with decreased TNF- production, their migration to draining
lymph nodes, compromising the subsequent induction of the
specific immune response. Furthermore, IL-10 can induce
long-term, antigen-specific anergy in CD4
 T cells. Thus, it is
intriguing that the possession of an anti-inflammatory genotype
(high IL-10 and low TNF- production) is increased signifi-
cantly in male centenarians [37]. High TNF- production may
be an important and necessary part of the normal host response
to pathogens, but its overproduction may cause immune-in-
flammatory diseases and eventually death. An anti-inflamma-
tory phenotype (high IL-10 production) may be highly advan-
tageous in the last decades of life, owing to the chronic proin-
flammatory status, which develops in the subjects with age [37,
38]. Thus, it is tempting to speculate that the presence of “high
IL-10/low TNF-” could be favorable in protecting against
age-related diseases, particularly, neurodegenerative diseases
[39, 40], but conversely, it could hamper the immune response
to infections and vaccine.
Overall, our study contributes to the understanding of the
effects of age on innate and adaptive immunity, which accom-
pany the response to influenza vaccine. It represents an im-
portant bridge between basic immune function and clinical
immunology in the hope of generating an effective reconstitu-
tion to improve immune response in the elderly. The results
obtained may contribute to define better strategies to improve
the response to vaccination in the elderly and underlie the
necessity to overcome immunosenescence at the moment of
vaccination to obtain a better response.
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